Literature DB >> 22300860

Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC.

Augusto Caraceni1, Geoffrey Hanks, Stein Kaasa, Michael I Bennett, Cinzia Brunelli, Nathan Cherny, Ola Dale, Franco De Conno, Marie Fallon, Magdi Hanna, Dagny Faksvåg Haugen, Gitte Juhl, Samuel King, Pål Klepstad, Eivor A Laugsand, Marco Maltoni, Sebastiano Mercadante, Maria Nabal, Alessandra Pigni, Lukas Radbruch, Colette Reid, Per Sjogren, Patrick C Stone, Davide Tassinari, Giovambattista Zeppetella.   

Abstract

Here we provide the updated version of the guidelines of the European Association for Palliative Care (EAPC) on the use of opioids for the treatment of cancer pain. The update was undertaken by the European Palliative Care Research Collaborative. Previous EAPC guidelines were reviewed and compared with other currently available guidelines, and consensus recommendations were created by formal international expert panel. The content of the guidelines was defined according to several topics, each of which was assigned to collaborators who developed systematic literature reviews with a common methodology. The recommendations were developed by a writing committee that combined the evidence derived from the systematic reviews with the panellists' evaluations in a co-authored process, and were endorsed by the EAPC Board of Directors. The guidelines are presented as a list of 16 evidence-based recommendations developed according to the Grading of Recommendations Assessment, Development and Evaluation system.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22300860     DOI: 10.1016/S1470-2045(12)70040-2

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  279 in total

1.  Cancer pain for the 21st century: stepping off the ladder, stepping up to new challenges.

Authors:  Sam H Ahmedzai
Journal:  Br J Pain       Date:  2014-11

2.  Diagnosis and management of breakthrough cancer pain: Have all the questions been resolved? A Delphi-based consensus assessment (DOIRON).

Authors:  J Porta-Sales; C Pérez; Y Escobar; V Martínez
Journal:  Clin Transl Oncol       Date:  2015-12-22       Impact factor: 3.405

3.  [Questions from a pain physician reader: Evidence, empiricism, eminence - all the same?].

Authors:  W Meißner; F Petzke; R Sabatowski
Journal:  Schmerz       Date:  2013-08       Impact factor: 1.107

4.  Changes of QTc interval after opioid switching to oral methadone.

Authors:  Sebastiano Mercadante; Giovanna Prestia; Claudio Adile; Alessandra Casuccio
Journal:  Support Care Cancer       Date:  2013-08-15       Impact factor: 3.603

5.  Long-term low-dose morphine for patients with moderate cancer pain is predominant factor effecting clinically meaningful pain reduction.

Authors:  Ru-Jun Zheng; Yan Fu; Jiang Zhu; Jiu-Ping Xu; Qiu-Fen Xiang; Lin Chen; Hua Zhong; Jun-Ying Li; Chun-Hua Yu
Journal:  Support Care Cancer       Date:  2018-05-31       Impact factor: 3.603

Review 6.  Breakthrough pain in elderly patients with cancer: treatment options.

Authors:  Sophie Pautex; Nicole Vogt-Ferrier; Gilbert B Zulian
Journal:  Drugs Aging       Date:  2014-06       Impact factor: 3.923

Review 7.  Effectiveness of the World Health Organization cancer pain relief guidelines: an integrative review.

Authors:  Cathy L Carlson
Journal:  J Pain Res       Date:  2016-07-22       Impact factor: 3.133

Review 8.  Cancer pain management: what's new?

Authors:  Jan Gaertner; Christine Schiessl
Journal:  Curr Pain Headache Rep       Date:  2013-04

9.  Opioid switching and variability in response in pain cancer patients.

Authors:  O Corli; A Roberto; N Corsi; F Galli; M Pizzuto
Journal:  Support Care Cancer       Date:  2018-10-24       Impact factor: 3.603

Review 10.  Pharmacological Treatment of Opioid-Induced Constipation Is Effective but Choice of Endpoints Affects the Therapeutic Gain.

Authors:  Salman Nusrat; Taseen Syed; Rabia Saleem; Shari Clifton; Klaus Bielefeldt
Journal:  Dig Dis Sci       Date:  2018-10-03       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.